Rahul Mannan

Assistant Research Professor & Director Histology Lab

University of Michigan
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (46)

Year:

2026

How cancer cells escape immune surveillance and resist immune checkpoint blockade (ICB) remains to be fully elucidated. By screening candidate genes frequently gained in cancer, we identified expression of ubiquitin-like modifier-activating enzyme 1 (UBA1) as being the most negatively correlated with signatures related to effector CD8+ T cells. High UBA1 expression was strongly predictive of treatment resistance and poor survival in ICB cohorts. Functional studies revealed that UBA1 mediated immune escape to promote tumor growth. Immune profiling further showed that Uba1 overexpression or depletion markedly decreased or increased functional intratumoral CD8+ T cells, respectively. Importantly, a selective UBA1 inhibitor, TAK-243, significantly synergized with ICB in multiple syngeneic models. Mechanistically, depletion or inactivation of the UBA1–STUB1 axis stabilized a key IFN pathway component (JAK1), enhanced IFN signaling, and elevated key immune modulators, including CXCL9, CXCL10, and MHC class I. Our study warrants clinical evaluation of the combination of UBA1 inhibitors and ICB. Significance: Our study reveals UBA1 as a predictive biomarker for clinical outcomes in ICB cohorts, mediating cancer immune evasion and ICB resistance. We further highlight JAK1 stabilization as a key mechanism of UBA1 inhibition and nominate the UBA1–STUB1 axis as an immuno-oncology therapeutic target to improve the efficacy of ICB.

Year:

2025

Year:

2025

FOXA1 is altered in 10 to 40% of prostate cancers, yet its oncogenic mechanisms remain uncharacterized in vivo. We developed knock-in mouse models representing distinct classes of FOXA1 mutations. Histopathological and multiomic analyses of prostate tissues and organoids revealed that Class 1 mutations, in conjunction with p53 inactivation, drive androgen-dependent adenocarcinomas through coactivation of mTORC1/2 and oncogenic AR signaling stemming from chimeric AR-half enhancers. By contrast, Class 2 mutations induce intraluminal plasticity by reprogramming differentiated luminal cells into a progenitor-like state through activation of KLF5 and AP-1 neo-enhancer circuitries, which enables enhanced survival and proliferation even under castrate androgen levels. Our findings establish FOXA1 as a multifaceted oncogene, with distinct mutational classes divergently evolving to drive prostate tumorigenesis or therapy-resistant progression.

Year:

2025

In single-cell transcriptomic analysis, accurate cell type annotation forms the essential basis for all downstream analysis and data interpretation. While time consuming manual annotation requires extensive prior knowledge, available automated cell annotation tools lack a unified, curated human cell reference to ensure successful identification of all cell types present in any given dataset. To fill in the gap we create “CellMap” a comprehensive single cell gene expression reference database of known cell types across most human tissues by compiling, curating and integrating single cell datasets from multiple sources including Human Protein Atlas, Tabula Sapiens, ArrayExpress and GEO. CellMap contains 151 different celltypes/states including 94 epithelial, 31 brain, 4 from soft tissues, 8 stromal and 15 major immune celltypes from 42 human tissues. Projecting pseudo-bulk profiles of the 151 celltypes into 2-dimensional UMAP revealed major clusters of cells from the nervous system, respiratory system, gastrointestinal tract, proximal digestive system, female tissues and endocrine tissues. Immune cells and stromal cells are generally clustered together regardless of their tissue origin. We also curated about 200 immune cell phenotypes from the ImmGen database for fine-tuning annotation of immune cell subpopulations. Importantly by combining CellMap and the SingleR algorithm, we successfully identified the cell lineage of the tumor and minor cell types originated from the biopsy site of a breast cancer metastatic sample; the latter were left unannotated with reference derived from breast tissue or misclassified using Human Primary Cell Atlas. In addition, CellMap allowed us to identify highly specific tissue markers and cell type markers. Based on 1241 identified marker genes, we trained a random forest model to predict cancer types using 80% of the TCGA tumor samples of each cancer type (n = 7160) and tested on a 20% hold-out testing set (n = 1774), achieving a median of 95.4% accuracy across cancer types. Cancer types with low accuracy include esophageal carcinoma (mostly mis-classified as head and neck squamous cell carcinoma) and rectum adenocarcinoma (mostly mis-classified as colon adenocarcinoma). The misclassification could be explained by the high similarity between these cancer types in terms of cell-of-origin. Finally a webportal for exploring celltypes in CellMap and an open-source R-package for automated cell annotation of single cell data and cell lineage prediction for bulk RNA-seq data were developed. This work provides valuable resources for conducting single-cell analysis and cancer cell-of-origin analysis. Additionally, it helps identify closely related cell types across tissue types, which is particularly useful since diseases originating from related cell types may share similar therapeutic targets. Citation Format: Yuping Zhang, Gabriel Cruz, Hanbyul Cho, Chandan Kumar-Sinha, Rahul Mannan, Jin Chen, Xuhong Cao, Saravana M. Dhanasekaran, Arul M. Chinnaiyan. CellMap: a comprehensive human single cell gene expression reference for automated cell annotation and cancer cell-of-origin analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1063.

Year:

2025

Androgen receptor (AR) signaling is critical for the survival and proliferation of prostate cancer (PCa) cells, thus making androgen deprivation therapy (ADT; e.g., castration) the mainstay for treatment. Notably, the oncogenic transcriptional functions of AR rely on a host of chromatin-binding regulatory proteins, which includes a pioneer transcription factor called FOXA1. FOXA1 de-compacts chromatin to enable DNA binding of AR and activation of target gene expression. Our lab found FOXA1 alterations to recur within three distinct structural classes in over 35% of metastatic castration-resistant PCa (mCRPC) cases in Caucasian White men. Subsequent studies reported FOXA1 mutations to be prevalent in over 40% of primary PCa in Chinese patients, thus positioning FOXA1 as a principal oncogene in this disease. Yet, the tumorigenic potential and pathobiology of FOXA1 alterations remain unexplored in vivo. Here, we have developed and characterized the first in-field transgenic mouse models that conditionally overexpress FOXA1 mutants in the prostate luminal epithelia. Our findings reveal that FOXA1 class1 mutations (i.e., wing 2 alterations) in a Trp53-null background drive high-grade, invasive luminal prostate adenocarcinoma with complete penetrance by 40 weeks. These lesions retain cardinal luminal features of the human disease, including regression upon androgen withdrawal. Mechanistically, the Class1 mutants reprogram AR and activate the PI3K/mTORC1 pathway to drive transformation. In contrast, FOXA1 class 2 mutations (i.e., C-terminal truncations) that are acquired in human mCRPC do not drive prostate luminal transformation in mice. Instead, these mutations induce intra-luminal plasticity by reprogramming differentiated cells into a progenitor stem-like state within androgen-replete normal tissues—a phenomenon otherwise induced upon castration. Class2 mutants lead to a 20-fold expansion of Ar+/Ck8+ luminal epithelia that gain expression of stemness markers such as Trop2, Ck4, and Psca. Mechanistically, we found the cistromically-dominant Class2 mutants to pioneer over 40, 000 neo-enhancer elements, bound by stemness-associated transcription factors, which instructed an androgen-insensitive luminal progenitor cell fate. Consistently, we found Class2-mutant mouse prostates to show minimal atrophy upon castration, with immunohistological assessment uncovering a higher density of Ki67+ luminal epithelial cells relative to both wild-type and Class1-mutant tissues. Collectively, our data establishes FOXA1 as a multifaceted oncogene in AR-dependent prostate cancers, wherein divergent evolution of FOXA1 mutational classes distinctly drive either cancer formation or therapy-resistant, intra-luminal plasticity during disease progression. These findings also represent the first report of FOXA1-driven prostate adenocarcinoma in mice. Citation Format: Sanjana Eyunni, Rahul Mannan, Yuping Zhang, Eleanor Young, Jie Luo, Jean Ching-Yi Tien, Qiuyang Zhang, Matthew Pang, Somnath Mahapatra, James George, Mustapha Jaber, Hamzah Hakkani, Sandra Carson, Abbey Todd, Noshad Hosseini, Ryan Rebernick, Xuhong Cao, Rui Wang, Fengyun Su, Rohit Mehra, Marcin Cieslik, Arul Chinnaiyan, Abhijit Parolia. Divergent evolution of FOXA1 mutations drive prostate tumorigenesis or therapy-resistant intra-luminal plasticity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3825.

Year:

2025

Background: Major histocompatibility complex (MHC) genes are critical for the adaptive immune system, enabling T-cells to detect and eliminate cancer cells. Many cancers evade immune surveillance by altering MHC expression, leading to resistance to immune checkpoint blockade (ICB) therapy. Understanding MHC regulation in normal and cancerous states is essential for developing effective immunotherapies. Previous studies using bulk RNA-sequencing failed to measure cancer cell-specific MHC expression accurately. This study aims to decode MHC transcriptional regulation in healthy tissues and cancers using single-cell RNA-seq (scRNA-seq) datasets and targeted CRISPR screens. Methods: We utilized a large-scale scRNA-seq dataset encompassing 18 tissues and 124 epithelial cell types to study MHC class I (MHCI) and class II (MHCII) regulation at baseline. After re-clustering and annotation, we investigated MHC expression across various cell types and tissues, quantifying heterogeneity using the Gini coefficient. We employed a master regulator inference approach with uni- and multi-regression models to identify transcription factors (TFs) predictive of MHC expression. To investigate MHC dysregulation in cancer, we curated 43 scRNA-seq datasets across 20 cancer types and 538 patients. Results: We observed an ∼8-fold range in MHCI expression across normal epithelial cell types, with notable MHCII expression in prostate club cells and cholangiocytes of the liver. Our approach nominated 104 TFs for MHCI and 107 for MHCII, including novel regulators like YBX1 and XBP1. In our pan-cancer analysis, we found widespread repression of MHC genes, with significant heterogeneity in MHCII expression among colon cancer patients correlating with mismatch repair deficiency. In prostate cancer, MYC-mediated pathways led to MHCI suppression, revealing a novel immune evasion mechanism. In an ICB cohort, TFs such as XBP1 and SP100 were strong predictors of patient survival. This work has resulted in a data descriptor to make single-cell ICB data accessible. Conclusion: Our study provides a comprehensive evaluation of MHC expression across 124 cell types and 20 cancers, identifying TFs predictive of MHCI and MHCII expression. By uncovering novel regulatory mechanisms and potential immune evasion strategies, this research contributes valuable insights into MHC regulation in normal and cancerous tissues. The identification of YBX1 and XBP1 as potential regulators opens new avenues for targeted therapies. The correlation between MHCII upregulation and mismatch repair deficiency suggests a potential biomarker for immunotherapy response. The discovery of MYC-mediated MHCI suppression provides a new target for enhancing immune recognition. These findings have important implications for understanding cancer immune evasion and may inform the development of more effective immunotherapies and predictive biomarkers for ICB response. Future work will focus on experimental validation of these computational findings and exploring their clinical applications in cancer immunotherapy. Citation Format: Mahnoor Gondal, Yi Bao, Rahul Mannan, Jing Hu, Arul Chinnaiyan, Marcin Cieslik. Single-cell Transcriptomics Unveils Novel Regulators of MHC Expression: Implications for Cancer Immunotherapy [abstract]. In: Proceedings of the AACR IO Conference: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2025 Feb 23-26; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(2 Suppl):Abstract nr A094.

Year:

2025

Year:

2025

Prostate cancer is driven by oncogenic transcription factor enhanceosomes comprising chromatin and epigenetic regulators. The lysine acetyltransferases p300 and CREB-binding protein (CBP) are key cofactors that activate enhancers through histone acetylation. Here we identify p300/CBP-mediated multisite histone H2B N-terminal acetylation (H2BNTac) as a defining feature of oncogenic enhanceosomes in androgen receptor (AR)-positive prostate cancer. p300/CBP are essential for AR and ETS transcription factor ERG transcriptional activity, and their dual degradation eliminates H2BNTac and histone H3 lysine 27 acetylation at hyperactive enhancers, leading to stronger suppression of oncogenic transcription than targeting either paralog or bromodomain alone. Cytotoxicity profiling across >900 cell lines revealed that tumors with high H2BNTac, including AR-positive prostate cancer, are selectively dependent on p300/CBP. In preclinical models, systemic p300/CBP degradation inhibited tumor growth, synergized with AR antagonists and showed no evident toxicity. These findings position H2BNTac as an epigenetic marker of enhancer addiction and establish dual p300/CBP degradation as a promising therapeutic strategy for enhancer-driven cancers.

Year:

2025

Lethal prostate cancer has passed through at least two evolutionary bottlenecks: acquisition of metastatic potential and development of castration resistance. A better understanding of how this affects genetic heterogeneity across metastatic sites is needed to develop strategies to block metastatic spread and to overcome resistance. By leveraging deep whole-exome sequencing of 93 tumors from 26 patients, we examined patterns of metastatic dissemination and clonal evolution of prostate cancer. Phylogenetic reconstruction and mathematical modeling enabled quantification of the number of mutations and clones in the cancer ecosystem and characterization of each patient’s disease as an evolutionary process. Although mutations of the earliest pathogenic genetic drivers of prostate cancer were truncal, most other likely passenger mutations, copy-number alterations, and clones arose after the cancer had spread and were confined to individual metastatic sites because of polyclonal and polyphyletic seeding. Single-tissue sequencing tended to overestimate mutation clonality and, apart from truncal drivers, underestimate mutation rates for both individual patients and cohorts. This study highlights the independent evolution of metastatic lesions, which has implications for diagnostic and targeted therapy strategies. Significance: Genomic analysis of a multisite metastatic prostate cancer cohort reveals patterns of clonal heterogeneity, dissemination, and evolution, highlighting the need to evaluate multiple samples to fully characterize the clonal architecture of tumors. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI .

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (21)

Yuping Zhang

Research Assistant Professor

University of Michigan

UNITED STATES
View details

Ulka Vaishampayan

Professor

University of Michigan

UNITED STATES
View details

Rohit Mehra

University of Michigan Medical School

UNITED STATES
View details

Arul M Chinnaiyan

University of Michigan

UNITED STATES
View details

Anbarasu Kumaraswamy

University of Michigan

UNITED STATES
View details

Robert Humble

Clinical Assistant Professor

University of Michigan

UNITED STATES
View details

Steven Kregel

Assistant Professor

Loyola University Chicago

UNITED STATES
View details

Jiali Yu

Professor

University of Science and Technology of China

CHINA
View details

Raymond Kostlan

Loyola University Chicago

UNITED STATES
View details

Heng Lin

Research Assistant Professor

University of Michigan

UNITED STATES
View details

Ilona Kryczek

University of Michigan

UNITED STATES
View details

Simpa Salami

University of Michigan

UNITED STATES
View details

weiping Zou

University of Michigan

UNITED STATES
View details

Eva Corey

Professor

University of Washington

UNITED STATES
View details

Colm Morrissey

Research Professor

University of Washington

UNITED STATES
View details

Abhijit Parolia

Research Investigator (Jr. Faculty)

University of Michigan

UNITED STATES
View details

Donald J Vander Griend

Professor

University of Illinois Chicago (UIC)

UNITED STATES
View details

Gabriel Cruz

University of Michigan

UNITED STATES
View details

Shaomeng Wang

Professor

University of Michigan

UNITED STATES
View details

Sandra Carson

Weill Cornell Medicine

UNITED STATES
View details

Costas A. Lyssiotis

University of Michigan

UNITED STATES
View details